Interviews

Discover the views of top healthcare experts!

Martin Widschwendter: How Molecular Science Could Transform Cancer Prevention

Professor Martin Widschwendter, is Director of the Daffodil Centre at Cancer Council NSW and an internationally recognised leader in women’s cancer prevention and translational epigenetics. His research focuses on using molecular, behavioural and environmental information to better understand individual cancer risk and enable earlier, more personalised prevention and detection. Professor Widschwendter’s work raises an important question for the future of healthcare: can we move from treating cancer earlier to predicting and preventing it earlier? In this interview, Professor Widschwendter discusses how advances in risk prediction and molecular science could transform cancer prevention, the potential of personalised approaches, and the challenges of ensuring that new prevention strategies benefit diverse and underserved communities. He also explains the potential of the WID®-easy test, a non-invasive approach designed to help identify women at higher risk of endometrial cancer and reduce unnecessary invasive investigations.

How close are we to predicting an individual’s risk of developing cancer and intervening before the disease develops? What needs to happen before this becomes part of routine healthcare?

We’re already further along than most people realise, at least for one cancer type. In cervical cancer, we’ve shown that a simple DNA-methylation test, WID-qCIN, run on the same swab already used for routine HPV screening, can forecast which HPV-positive women will go on to develop a serious pre-cancer or invasive cancer, not just detect it once it is there. In a real-world screening population of over 28,000 women in Stockholm, combining WID-qCIN with HPV16/18 genotyping predicted around 69% of the high-grade abnormalities that only became apparent one to six years later, compared with about 18% predicted by cytology alone meaning fewerfollow-up colposcopies were needed to find each case. That is a genuine window to act: closer monitoring or earlier treatment for those flagged as high risk, and the realistic prospect of safely extending the screening interval, potentially to five years, for women shown to be at low risk. Before this predict-and-intervene logic extends routinely across other cancers, three things need to fall into place. First, we need dynamic, repeatable biomarkers that can show a preventive action is actually working, the way blood pressure or cholesterol do in heart disease. Cancer currently has no real equivalent of that feedback loop; DNA methylation is the strongestcandidate currently, because it is measurable from the same accessible samples used for risk prediction. These tools need validating in large, diverse, population-representative cohorts rather than research centres alone, with honest reporting of what is established, what is research-stage and what remains aspirational. Health systems need to build the self-sampling, risk-communication and equity infrastructure to deliver this fairly, so that earlier risk prediction benefits everyone and does not simply widen existing gaps in who gets screened.

Your research combines molecular and epigenetic data with environmental and lifestyle factors. How could this change the way we understand cancer risk and approach prevention?

Epigenetics, particularly DNA methylation, is where biology meets environment. It is the layer of the genome that records cumulative exposure being, hormones, ageing, the air we breathe, what we eat or if we smoke, imprinted onto our cells over years, long before a tumour is detectable. Smoking is a clear illustration of why this matters for prevention. Across more than 3,500 buccal, saliva, cervical and blood samples, we identified over 500 distinct DNA-methylation changes linked to smoking, falling into clear patterns depending on cell type and which tissue was directly exposed to smoke. Strikingly, e-cigarette users, even those with far shorter and lighter smoking histories, showed many of the same epigenetic alterations as cigarette smokers, despite long-standing messaging and myths that vaping is around 95% less harmful. Some of the same changes were also found to be elevated in lung cancer tissue itself and in progressing pre-cancerous lung lesions, and in buccal (cheek-swab) samples could flag future lung cancer risk up to 22 years before diagnosis. This reframes how we think about risk. Rather than treating ‘tobacco smoker’ or ‘vaper’ as a single category, we can measure the actual molecular damage an individual’s own cells have accumulated from a given exposure. Encouragingly, we also found that some of these changes partially reverse after someone stops smoking. That dual property, a signal that reflects real exposure and then moves again on quitting, means the same biology can eventually serve two purposes in prevention: flagging who is at elevated risk from a specific environmental or lifestyle exposure, and showing that person, in close to real time, that changing their behaviour is measurably changing their underlying biology and reducing their risk. That is a far more personal and motivating basis for prevention than a general population-level warning alone, and it is exactly the kind of dynamic, lifestyle-linked marker that a genuinely preventive, rather than purely diagnostic, cancer strategy needs.

You founded the EUTOPS Institute in 2020. What led you to establish the institute, and what role does it play today in cancer prevention and early detection?

I founded EUTOPS, the European Translational Oncology Prevention and Screening Institute, in Hall in Tirol, Austria, at the invitation of the Tyrolean state government, after close to two decades developing cancer early-detection and prevention science at the University of Southern California and then University College London. The motivation was straightforward. Cardiovascular medicine spent decades building a simple, shared logic around a few cheap, repeatable markers – blood pressure and cholesterol – to predict risk, match prevention to that risk, and confirm whether treatment was working. That approach transformed outcomes for heart disease. Cancer has never had an equivalent, despite the underlying biology increasingly being there to build one, and I wanted a dedicated institute whose sole purpose was closing that gap. EUTOPS has run the population-scale studies behind our DNA-methylation-based WID (Women’s cancer risk IDentification) test family, covering cervical, endometrial, ovarian and breast cancer risk, in partnership with groups including University College London, the Karolinska Institutet in Stockholm and now the Daffodil Centre, a partnership between Cancer Council NSW and the University of Sydney. Its role is specifically translational: taking discoveries about the epithelial epigenome out of the laboratory and into validated, minimally invasive, often self-sample-compatible tests that can be trialled in real health systems, including the NHS pilots now under way in the UK, rather than leaving them as research findings alone.

You developed WID®-easy, a non-invasive test for assessing the risk of endometrial cancer in women with postmenopausal bleeding. How could it change the way these women are assessed and treated?

Postmenopausal bleeding is the classic alarm symptom for endometrial (womb) cancer, but in roughly 97% of cases the cause turns out to be benign. The current first-line test, transvaginal ultrasound, is reasonably sensitive but has poor specificity, gives an inconclusive result in about 60% of women, and research suggests the diagnositic performance of transvaginal ultrasound may vary across different population groups and in serous cancers – the subtype with the poorest prognosis. Each inconclusive or positive scan currently leads to an invasive, often painful biopsy or hysteroscopy, the majority of which find nothing. WID-easy changes that pathway. It is a simple vaginal/cervicovaginal swab, analysed by PCR for DNA methylation at two genes (ZSCAN12 and GYPC), with laboratory logistics similar to a COVID-19 test and results within a few days. In the largest validation studies to date it reached over 95% sensitivity and a negative predictive value above 99.7%, with a far lower rate of inconclusive results than ultrasound (below 2% versus up to 38%). In practical terms, roughly two women need a biopsy to find one cancer using WID-easy, compared with around nineteen under the standard ultrasound-led pathway, a reduction now reflected in the German national (S3) clinical guideline for endometrial cancer, and in an NHS cost-modelling analysis showing it could save over £150 per patient while needing definitive follow-up testing for only about 12% of women, instead of 57%. We are now seeing this tested succeessfully piloted in several UK NHS Trusts. For most women with postmenopausal bleeding, that means a fast, reassuring result from a simple swab rather than weeks of waiting and an invasive procedure; for the minority at genuine risk, it means being fast-tracked to the investigation they actually need.

How can we make sure that advances in cancer prevention also reach women in underserved, rural and remote communities?

This is one of the real practical advantages of molecular, DNA-based tests over tests that depend on imaging equipment or a specialist examining cells under a microscope. Because the result comes from measuring DNA methylation rather than interpreting cellular architecture or an ultrasound image, the sample itself does not need to be collected or read by a specialist on site, it can be self-collected by women at home, at a community clinic, or during a mobile outreach visit, then simply posted or couriered to a centralised laboratory for automated, objective analysis. No ultrasound machine, no colposcope and no on-site specialist is required at the point of collection. We already have good evidence this model works. HPV self-sampling for cervical screening reliably increases participation, especially among women who have never attended a clinic-based screen, and that same self-collected cervicovaginal swab underpins our WID tests for cervical, endometrial and ovarian cancer risk. We have also shown that WID-qEC performs just as well in a cohort of women in Ghana as in the UK,which is important given how disproportionately expensive a hospital-based ultrasound pathway is, relative to local incomes, in many under-resourced settings. But the underlying science only solves part of the problem; reaching rural, remote and underserved communities also requires deliberate investment in the logistics around the test. Reliable kit distribution and return, plain-language and translated materials, and ways of delivering results that do not assume internet access or a smartphone. Because none of these molecular tests depend on cellular context, several could, in principle, be combined into a single consolidated sample; buccal, cervicovaginal, urine or faecal, rather than a separate appointment and specimen for every cancer type. That is exactly the low-touch-point model that remote and under-served communities need, and building it, not the laboratory science itself, is now the main thing standing in the way.

Share Your Opinion, Publication, or other Engagement!

Share Your Opinion, Publication, or other Engagement!

OUR NEWSLETTER

© 2026 New Healthcare d.o.o. All Rights Reserved.